Delivery Order SPE2DP20D0002-SPE2DP24F7999

Award Date 9/18/24
Potential Completion Date 9/24/24
Potential Value $476K
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $635,218.92 firm-fixed-price delivery order contract to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccines. This contract has a period of performance through May 21, 2024. Teva Pharmaceuticals USA, Inc. has provided Adenovirus Type 4 vaccines to the DLA Troop Support Medical through numerous previous delivery order awards, typically ranging...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $317,609.46 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Teva with DLA Troop Support Medical for providing critical pharmaceuticals to support military immunization programs. Teva has also been awarded other significant...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $476,414.19 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide Adenovirus Type 4 vaccines. This contract, which has a completion date of May 21, 2024, supports military immunization programs. Teva Pharmaceuticals USA, Inc. has a long history of supplying critical pharmaceuticals, including other vaccines and medications, to various federal...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a $317,609.46 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide Adenovirus Type 4 vaccines. This order has a completion date of January 30, 2024 and is not a set-aside contract. Teva Pharmaceuticals USA, Inc. provides critical pharmaceutical products to federal agencies like the Department of Veterans Affairs (VA), Department of Defense (DOD),...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of Adenovirus Type 4 vaccine, a critical product for military immunization programs. The $158,804.73 firm-fixed-price contract has a period of performance through March 26, 2024. Teva Pharmaceuticals USA, Inc. has been awarded numerous prime federal contracts and delivery orders from...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $635,218.92 firm fixed-price delivery order (SPE2DP24F7177) to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This order is part of a larger Indefinite Delivery Contract (SPE2DP20D0002) held by Teva to provide essential medications to federal agencies such as the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a $317,609.46 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide Adenovirus Type 4 vaccine. This delivery order has a completion date of January 30, 2024. Teva Pharmaceuticals USA, Inc. is the prime contractor and there is no set-aside designation for this award. The company has previously fulfilled multiple federal contracts and...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $158,804.73 firm-fixed-price delivery order contract (SPE2DP20D0002|SPE2DP24F3909) to provide Adenovirus Type 4 vaccines. The contract has an ultimate completion date of April 30, 2024 and is an unrestricted award, not set aside for any specific business type. Teva Pharmaceuticals USA, Inc. currently holds several major indefinite...
The Defense Logistics Agency Troop Support Medical awarded a $282,353.76 firm fixed price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This award is not associated with a set-aside contract. Teva Pharmaceuticals has a history of providing pharmaceutical products, including vaccines, antiviral medications, respiratory treatments, and multiple sclerosis drugs, to federal customers such as...
The Defense Logistics Agency (DLA) Troop Support Medical awarded a $476,414.19 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 A vaccine. The contract has a completion date of January 30, 2024 and does not have a set-aside designation. Teva Pharmaceuticals USA, Inc. has been awarded numerous prime federal contracts to supply critical pharmaceutical products to the Department of...
  • SPE2DP20D0002
    Indefinite Delivery Contract
  • SPE2DP20D0002-SPE2DP24F7999
    Delivery Order

The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm-fixed-price delivery order contract to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. The contract has a ceiling value of $476,414.19 and a completion date of September 24, 2024. This delivery order is part of Teva's ongoing role as a major supplier of critical drug products to various federal agencies, including the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons, and Indian Health Service. Teva holds several significant Indefinite Delivery Contracts (IDCs) with these agencies, such as a $64,352,514.80 contract for glatiramer acetate injections and a $109,085,460 contract for Albuterol HFA inhalers, demonstrating its crucial position in maintaining the pharmaceutical supply for federal healthcare programs. This particular award for the Adenovirus Type 4 vaccine is not designated as a set-aside contract.

Generated 12/18/24, 9:11 AM